In previous notes, we wrote about the comparative advantage of Mexico and India relative to China from a global manufacturing standpoint: “Made in Mexico” on July 6, 2023, and “Slumdog Millionaire Could Eat Wolf Warrior’s Lunch” on August 3, 2023. This week, we examine how and where the opportunities should materialize within Mexico and India on their own merits, rather than simply as replacements to China.

Our analytical framework consistently examines four drivers that shape the global economy: demography, international relations, technology and the regulatory backdrop. For the foreseeable future, climate change and social inequalities are also important factors that should not be ignored. Our analysis indicates that the next ten years will be chaotic globally because the large Baby Boomer generation is retiring, being replaced by the much smaller Gen Z, while populism and zero-sum calculus is steering international relations. Meanwhile, artificial intelligence and robotics have reached the implementation phase which could bring great productivity improvement at a time when regulatory oversight is lagging. Meanwhile, the earth is getting warmer and social inequalities are reaching levels that have historically resulted in a popular sense of resentment.

Considering this global context, we find that India and Mexico are better positioned than most countries. On demographics, they have a young and growing population without the baby boomer retirement issue. Contrary to most other countries, they have more residents in the 10-20 year-old cohort than in the 50-60 year-old age group. The chart below highlights the difference between Mexico and India’s similar profiles versus China. We use China, but Europe and Japan also have a lot more upcoming retirees than new workers.

On geopolitics, Mexico is located next to the largest consuming country in the world, with which it has a free trade agreement. India, by not being strategically aligned to a specific group of countries, is courted by both the United States and China. Geographical factors can influence economic opportunities and trade dynamics. Both India and Mexico have strategic geographical locations that facilitate trade as the map below highlights. Mexico's proximity to the United States makes it a key player in North American supply chains, while India's location provides access to emerging markets in Asia, Africa, and the Middle East.

On the negative, the map also spotlights the risk resulting from social inequalities in Mexico and India with GINI coefficients of 46.1 and 35, respectively, in 2019. These inequality levels are not as dire as those in Brazil and South Africa – as measured by the GINI coefficient - but they are still relatively high. Also, since both countries are close to the Equator, it puts them at greater risk from climate change.

For the last two drivers: technology and regulation, both represent opportunities and risks. India is producing a large number of engineers that can harness technology, but artificial intelligence and robotization will reduce the demand for workers. For regulations, we cannot affirm that Mexico and India are regulatory leaders with political interference and lots of red tape, but they have shown some progress over the years.

 

Structural Trends

Considering our perspective on the six drivers examined above, we are optimistic on the structural paths of India and Mexico. The picture below highlights the areas where investors should focus for sustainability impact: infrastructure and essential services. More consumers and greater household formation levels lead to more purchases of food, cell phones, housing-related items, technology and financial services. To support this larger and younger population, infrastructure needs will increase for education, water, telecom, electricity, hospitals and waste management, among others.

Both India and Mexico are vulnerable to various climate change impacts, and these effects can manifest across different sectors. Some potential risks for India and Mexico are highlighted below.

 

These climate risks compound the need for improved infrastructure and essential services like water, electricity, food and medical supplies.

 

Infrastructure

On infrastructure, we looked for sustainability leaders that will participate in the infrastructure expansion and respond to climate change issues. Larsen & Toubro, in India, is a diversified company involved in infrastructure and heavy industries. It builds roads, bridges, airports, energy transmission and production. Orbia, in Mexico, is similar as it is involved in a similar sector with a greater emphasis on agriculture. In the materials industry, Cemex in Mexico, is a leader in low-carbon cement and has a Science-Based Target Initiative (SBTi) objective consistent with 1.5 degrees of warming. For telecom and the electric grid, Bharti Airtel and Power Grid of India are strong candidates.

 

Essential Services

With that in mind, we searched for locally focused sustainability leaders well positioned to respond to increased internal demand. Consumer staple companies that fit the bill include Hindustan Unilever in India and Walmex in Mexico, while in the financial services industry: HDFC in India and Banorte in Mexico tend to be leaders. Infosys is a promising technology play.

The chart below displays their overall sustainability performance using their sustainability percentile score from CSRHub.

Have these drivers led to strong equity performance since the beginning of the decade? The chart below shows the performance for the companies we discussed regrouped according to their sector of activity. We are using a short history and small sample of companies but a wide dispersion of results is evident: Infrastructure in India has done amazingly well but the same cannot be said for Mexico. Essentials have behaved decently in both countries. The stronger performance of infrastructure in India coincides with a strong push by the government with the “Make in India” program. In Mexico, political interventions have contributed to the poor performance of the infrastructure sector.

Temporary employment is a well-known leading indicator of job market health. Temp agencies – with their ability to quickly instate and terminate short-term contracts – give an excellent lead on the overall health of the job market (see the chart of U.S. data below). Already, temp agencies have seen a marked slowdown in the number of worker placements, a sign of what’s likely to come for the overall job market.

Many of the major players in the temp staffing industry had a fantastic stock price performance from late 2020 to spring 2022. However, these companies did not participate in the 2023 tech-led bull market; the top four temp agencies all posted negative stock price returns in 2023.  This seems appropriate, given that profits at these companies are positively correlated with employment growth (and overall economic growth). 

Indeed as Manpower - a major staffing company - explained in it’s most recent annual report, “improving economic growth typically results in increasing demand for labor, resulting in greater demand for workforce solutions and staffing services…During periods of increasing demand, we are generally able to improve our profitability and operating leverage as our cost base can support some increase in business without a similar increase in selling and administrative expenses…When demand drops, our operating profit is typically impacted unfavorably as we experience a deleveraging of our selling and administrative expense base as expenses may not decline at the same pace as revenues.”

Judging by the magnitude of previous employment cycles, it is reasonable to expect that staffing companies are likely to see further slowdown in the demand for their services, and hence their stock prices. Investors concerned with sustainability need to be extremely discerning in the staffing sector as many of these companies have nefarious compensation schemes and neglect to report on material activities.

In today’s note, given the unfavorable macro prospects for this sector, we concentrate primarily on short-selling opportunities in companies that have adverse practices.

Note that most countries have some form of temporary labor market where staffing agencies act as the middleman between prospective employers and employees, but the reliance on temporary workers varies significantly. In the U.S., temp work currently accounts for only 2% of recorded employment, whereas in the euro area, it accounts for over 17%. Some of the gap is due to measurement differences but it is mainly due to the fact that European employers typically must pay greater severance and face great restrictions on firing permanent employees; an incentive for European employers to hire workers on temporary contracts when possible. That said, in the U.S. there is far less regulation of temp workers, and no limit on duration or guarantee of equal treatment. Ergo, for the 2% of temp workers in the U.S., the stakes are far higher.

Part One: The Issues With Temp Staffing Agencies

Sustainable Market Strategies’ Labor Fairness investment theme focuses on competitive wage practices, skills training, and generous benefits and health insurance. These characteristics identify quality employers that in turn face lower employee turnover rates and risk of strike disruption.

Staffing agencies can theoretically fit this bill and have an important role in the labor market. After all, agencies facilitate access to employment across a myriad of industries. In some countries, notably the euro area, temporary staffing is a well-regulated industry with limited discrepancies between temporary and permanent staff. However, this is not the case in markets like the U.S. and Canada. In stark contrast to material labor topics included in the SASB framework, temp workers face issues of unfair compensation, inadequate health and safety training and discrimination.  The U.S. industry of temporary staffing in particular is clearly in need of an overhaul with laggards being the most at risk from a tighter labor market or a policy change. The Restoring Worker Power Act (tabled in 2020 but not passed before the end of the congressional session) would have required equal pay for equal work, stronger data disclosure from staffing agencies including conversion to permanent positions, race and gender diversity.

Focusing on temp workers in the U.S., a survey of over 1300 such workers showed 24% of respondents had experienced issues of receiving pay below the minimum wage, failing to be paid for overtime or the total number of hours worked. Incredibly, 35% of those surveyed held their current position for over a year, and 18% had at least a two-year tenure! A comparison of the median wages for temp workers versus total employees by industry illustrates how temp workers are getting paid less for similar jobs.  

In addition to pay inequality, there is also evidence of a lack of proper training as well as instances of discrimination at staffing agencies. Inadequate training is especially precarious in higher risk industries like construction, warehousing and manufacturing where temp worker are twice as likely to be injured on the job. While temporary staffing could be seen as a positive for minority groups (black and Latinx are overrepresented in the temporary workforce), low-quality jobs – characterized by the poorest working conditions, sometimes termed “low road” employment - are assigned to Black and Latinx persons at a higher rate.

Part Two: How The Main Companies Stack Up

We looked at the largest (by market cap) staffing services companies in Europe and North America. From a sustainability perspective, it is challenging to find quality disclosures on temporary workers in the company reporting of staffing agencies. Indeed, CSRHub scores on reporting and transparency are generally weak across the sector, underscoring that these companies are poor at reporting on material topics. With the exception of ManPower Group, none of the companies report on the number of contract workers in accordance with the SASB disclosure topic or provide any relevant SASB metric.

Given the lack of reporting based on SASB, we use CSRHub scores that align with material topics in the staffing services industry to gauge the sustainability of staffing companies. Note that CSRHub scores may be artificially inflated by disclosures that are based only on direct employees and not the temp workers they are placing.  CSRhub scores related to compensation stand out as especially weak, likely a reflection the occupational data shown in the previous table: staffing agencies provide inferior wages to temporary employees.

 

Note that all four of the large staffing companies draw the majority of their revenues from placing temporary workers, while consulting and permanent placements (i.e. jobs with less pay discrepancy) account for only a small share of their business.

Overall, the adage that “staffing agencies work for the employer not the employee” appears to ring true. While these companies fulfill the function of matching job seekers to employers (thus decreasing friction times in the labor market), their business model is built on offering below-market compensation to workers; these companies make good potential short candidates within sustainable investment portfolios.

In the table below, we provide the financial characteristics of our sample companies. Some points stand out:

As the sustainable investing industry continues to mature, participants seek investment opportunities in themes beyond climate change and renewable energy. One of the increasingly popular themes in the social investing space is financial inclusion.

Far be it from us to pretend that this topic is new – we have written several notes on this subject, including “Banking on Impact” on August 31, 2023, and “Three (Sexy) Banking Plays to Change the World” on September 8, 2022.

It’s time to re-visit this subject given inclusion of some of these companies in supposed “impact” funds that has us raising our collective eyebrows.

The increase in popularity of the financial participation theme also entices some companies to try to brand themselves with the “financial inclusion” label, knowing it could attract investors. This is another form of greenwashing – this time the green is for the color of the money!

Take the recent story involving a Nasdaq-listed company called Tingo Group and Agri-Fintech Securities (TIO US). For years, it defrauded investors on the basis that it was providing financial products and services to millions of Nigerian farmers. Tingo was even included in a handful of Article 8 and 9 funds on that basis. Following a report by the US-based short seller Hindenburg Research last year, the SEC recently concluded that Tingo inflated its accounts with ‘billions of dollars of fictitious transactions’ and was in fact an empty shell with no products and even fewer clients.

However, when done right, financial inclusion can be a significantly impactful sector. After all, there is a growing recognition of the importance of financial inclusion as a catalyst for sustainable development. Governments, financial institutions, and international organizations are increasingly focusing on strategies to expand access to financial services as it is positioned prominently as an SDG enabler; it is featured as a target in eight of the seventeen Sustainable Development Goals, with notable positive impact on gender equality, poverty, health and education.

The latest iteration of the World Bank's Global Findex, a comprehensive survey conducted every three years to assess the state of financial inclusion worldwide, reveals a startling reality: nearly a quarter of the global population is without a formal bank account. This basic financial service is a cornerstone of financial inclusion, yet access to it is uneven across different demographics, influenced by factors such as nationality, gender, income levels, and educational background. Thankfully, mobile money accounts are rapidly becoming an alternative to traditional banking in the developing world.

The goal of achieving universal financial inclusion is not only about providing financial services but also about creating a financial system that will improve the socio-economic conditions of the underserved and undervalued populations.

Yet, it seems that some portfolio managers are quick to put in the “financial inclusion” bucket pretty much any company that operates in the financial or fintech sectors and that serves populations in developing countries.

Let’s use three company examples active in South America that are often found in various forms of impact funds: dLocal (DLO US), Nu Holdings (NU US) and MercadoLibre (MELI US).

On the surface, dLocal could be attractive for investors who care about financial inclusion. They are a pure play fintech company operating out of Uruguay and Brazil and derive more than 90% of their revenues almost exclusively from emerging and frontier markets. But behind the financial inclusion buzzwords, they operate a payment platform that, in a nutshell, facilitates transactions between the largest tech firms (Amazon, Google, Uber, etc.) and customers that are underserved by mainstream payment providers such as Visa or MasterCard. Moreover, they charge above-market fees (up to 7%) for that service. The social impact is minimal and dLocal would be a questionable name to include in an impact fund.

Nu Holdings, or Nubank as it is commercially known, has a slightly better financial inclusion story, but we are still not completely convinced the company is making a substantial impact. True, Nubank brought six million Brazilians into the financial system for the first time by allowing them to open a digital bank account in just a few steps. This is undoubtedly good. But beyond that financial inclusion story – which is what they want you to know about them – they derive the vast majority of their revenues from the remaining 70 million clients they serve. Much like other consumer finance companies, the main way they generate revenues is via fees and interests paid on loans. For Nubank though, 80% of the interest paid to them come from their credit card segment, which charges up to 20% a month in interest fees, or up to 200% a year! While this is in line with other Brazilian financial institutions, generating this much revenue from credit card loans as opposed to more socially productive personal or business loans hurts their financial inclusion credibility. Though not entirely convinced, we understand why some managers include this name in the financial inclusion theme.

The case for impact investing is easier when it comes to MercadoLibre, which is Latin America’s largest ecommerce platform and emerging as a leader in the region’s financial technology (fintech) industry. In 2021, the firm served 51.5 million individual fintech customers. Additionally, 900,000 households identified MercadoLibre’s platform as their primary income source. On average, the platform was responsible for the creation of 6 jobs every hour. Throughout the year, more than half a million small-to-medium enterprises (SMEs) utilized the platform for sales. The company has a net positive impact through its democratisation of commerce and financial services. It aims to level the playing field between large and small vendors, and to make payments and commerce processes simpler, safer and more efficient for all.

The U.S. healthcare system is distinct from other developed economies, marked by its absence of universal coverage and a complex mix of private and public elements. This makes healthcare accessibility and affordability ongoing national challenges and also presents important opportunities and risks for sustainability investors. After all, the enjoyment of the highest attainable standard of health is considered a fundamental human right.

America’s Dysfunctional Healthcare System

Despite spending the most on healthcare compared to other rich countries, as illustrated in the chart below, the U.S. has worse outcomes for metrics such as life expectancy, avoidable hospital stays, suicides, and maternal mortality.

About 65% of Americans rely on private health insurance, but the quality and cost of coverage is extremely heterogeneous. Moreover, nearly 26 million American (8% of the population) are uninsured or underinsured. The table below provides a snapshot of health coverage distribution in the U.S. 

This discrepancy in coverage is further exacerbated by the U.S.’ complex drug pricing system. The U.S. healthcare system is characterized by its limited capacity for insurers to effectively negotiate drug prices, in stark contrast with nations like Germany where government-led negotiations help maintain cost controls. This disparity in bargaining strength contributes to higher medication costs in the U.S. The chart below shows the complex journey of how drugs are priced, involving many players including consumers, pharmacies, wholesalers, and manufacturers.

Insurers, through negotiated payments and rebates with Pharmacy Benefit Managers (PBMs) and drug manufacturers, struggle within a system that favors opaque transactions and inhibits straightforward price bargaining. This visual representation underscores the critical vulnerability in how the U.S. manages prescription drug pricing, driven by market dynamics rather than patient need and health outcomes.

In the face of such complexity, costs for crucial medications like insulin have soared, as we discussed in the note “Basic Instinct: The Insulin Profit Machine” (September 22, 2022). These costs are born by those with private insurance and also by public healthcare programs.  

 

The Patchwork of Public Healthcare

In a system with no universal coverage and high drug prices, government initiatives like Medicare and Medicaid play a vital role, offering an alternative to private insurance to more vulnerable populations. Established in 1965, Medicare provides health insurance for those aged 65 and older, while Medicaid caters to people with limited income; both are funded through taxes from employees and employers.

Medicare, comprising Part A (hospital insurance), Part B (medical insurance), Part C (advantage plans) and Part D (prescription drug coverage), cover most healthcare services, but not all, with the costs partially shared by the insured. This cost-sharing structure underscores the critical role of these programs, especially since there has been a steady increase in the share of Americans covered by Medicare and Medicaid (see chart below).

 

The increase in Medicare beneficiaries coincides with an ageing population, which is leading to exploding costs, projected in the following chart:

It is notable that in 2010, the Affordable Care Act (ACA) was the first major regulatory change to Medicare and Medicaid. The aim of the ACA was to expand coverage and was successful at eliminating some coverage gaps, although 8% of the population still remain uninsured. What’s more, these efforts, while critical in expanding access, came with substantial fiscal implications for the government: in 2021, Medicare spending comprised 13% of the federal budget and 21% of national healthcare spending.

 

Next Battle: Addressing Drug Prices

The next battle for improving the U.S. healthcare system involves tackling high drug prices. The Biden administration campaigned on a promise to lower the cost of prescription drugs and intends to make lowering healthcare costs a theme of the 2024 re-election campaign. This follows on its initial tackling of prescription drug prices in the Inflation Reduction Act of 2022. The act includes provisions to lower prescription drug costs for Medicare beneficiaries and to reduce federal drug spending. A notable aspect of this legislation is the cap on insulin costs at $35 per month for seniors on Medicare since January 2023.

Following this legislative change, Eli Lilly and Novo Nordisk – major producers of insulin - announced in early 2023 significant price reductions and expanded accessibility programs. Eli Lilly announced reducing prices for key insulin, impacting 10.5% of its U.S. revenue, and the expansion of its Insulin Value Program (that caps out-of-pocket costs at $35 per month). Novo Nordisk's price cuts, effective for several of their insulin products, will influence 59% of their insulin sales in the U.S. Despite these changes, advocacy groups like T1International demand further reductions, highlighting the significant gap between production costs and retail prices.

In a broader context, the IRA mandates the federal government to negotiate prices for select high-expenditure drugs covered under Medicare Part B and Part D, starting in 2026. This measure aims to put downward pressure on Part D premiums and out-of-pocket costs for Medicare beneficiaries. The program is projected to save $98.5 billion over ten years, although the pharmaceutical industry cautions that it might deter the development of new drugs,. The Congressional Budget Office (CBO) projects that the impact of these provisions on the introduction of new drugs to the U.S. market will be very modest (i.e. a potential reduction of 1% over the next 30 years, which translates to about 13 fewer drugs out of an estimated 1,300 new drugs. In other words, the Act offers solutions to control costs while expanding coverage, without stifling pharmaceutical innovation.

The Medicare drug price negotiation process targets high-cost drugs, with the inaugural selection representing 20% of Part D costs, or $50.5 billion, from mid-2022 to mid-2023. These drugs are produced by major pharmaceutical companies, and often account for a significant share of their revenue (see table below).

Following the U.S. government's announcement about Medicare drug list for price negotiations at the end of August, AbbVie disclosed a $2.1 billion charge in anticipation of reduced revenue from its cancer drug Imbruvica. Six pharmaceutical manufacturers—Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson and Merck—took the Biden administration to court in an attempt to block the negotiation program, but finally agreed in early October to negotiate drug prices with the government.

Pharma Under Pressure

Since the IRA was announced, the performance of U.S. big pharma stocks has lagged the broader S&P 500 Index. Removing the effect of the largest tech companies and using the equal-weight S&P 500 index (the latter corrects for the massive performance bias of the Magnificent 7) shows U.S. big pharma stocks have slightly outperformed. However, within U.S. big pharma, Eli Lilly has been the star performer, up 96% during the period, primarily due to the obesity drug craze (see note “You Can Have Your Cake and Eat it Too” from November 16, 2023). The rest of U.S. big pharma have underperformed by a substantial margin (as seen in the chart below). We believe that government regulation is hanging a dark cloud over the industry and is affecting industry performance, just another example of how fiscal policy and regulation influence market performance in the current era.

With only the initial phase of negotiations underway, there is potential for further impact on other major pharmaceutical companies in the subsequent rounds, with ultimately 60 drugs to be affected between 2026 and 2029. Of course, this is highly dependent on the outcome of the 2024 election; Republicans are not in favor of interventionist pricing.

The table below highlights the drugs (and the companies producing them) that represent the highest costs in Medicare Part D, as of 2021, which could potentially be implicated in future Medicare negotiations.

 

Overall, the IRA represents a serious government effort to address high prescription drug costs in the United States. While the Medicare drug price negotiations specifically target costs for government-funded healthcare, there is potential for a ripple effect that could lead to broader price reductions if negotiations set new benchmarks for drug pricing. This could have a meaningful impact on pharmaceutical companies.

“Wegovy” and “Ozempic” have become household names in the blink of an eye: in 2023, the number of prescriptions for these anti-obesity medicines exploded, bringing with it a surge in hope that one major public health concern can finally be tamed. After all, obesity contributes significantly to the burden of chronic diseases and imposes substantial economic costs on societies.

Not surprisingly, the promise of these new drugs has also brought excitement to equity investors. Who really wins and loses from a “miracle” drug that provides a wholesale cut to calorie consumption by way of appetite suppression? In today’s Note, our Q&A addresses key considerations for sustainability-minded investors by exploring the viability of anti-obesity drugs and their potential implications for food stocks.  

Question #1: What are these new weight-loss drugs?

The story of GLP-1 receptor agonists – the scientific descriptor for obesity drugs like Ozempic and Wegovy – is a fascinating tale of scientific curiosity, serendipity, and perseverance. In the 1990s, a group of scientists at Novo Nordisk were studying the venom of the Gila monster, a lizard native to the southwestern U.S. They were interested in the venom’s ability to lower blood sugar levels and discovered that the venom contained a hormone with similar structure to glucagon-like peptide-1 (GLP-1), the now famous naturally occurring hormone that stimulates insulin secretion. A first GLP-1 receptor agonist, Exenatide, was approved in 2004 for treatment of type 2 diabetes. But the real revolution happened during the clinical trials in 2017 for another GLP-1 receptor agonist, the infamous Ozempic, when participants with obesity who received Ozempic lost an average of 15% of their body weight, compared to just 2.4% for those who received a placebo. The weight loss results from this diabetes drug were so impressive that Wegovy, a higher-dose version of Ozempic, was approved by the FDA for the treatment of obesity in 2021.

While Novo Nordisk was first and continues to dominate the market, other Big Pharma players are not letting this massive opportunity slide. Eli Lilly, Novo’s century-old rival in the insulin space, just got its own GLP-1 receptor agonist, Tirzepatide a.k.a. Mounjaro, approved for use as a weight loss treatment under the name Zepbound by both US and UK regulators last week. In total, there are about 8 to 10 other GLP-1 receptor agonists currently approved for diabetes but with known weight loss co-benefits that could eventually be approved for obesity, which would significantly improve the competitive landscape.

Question #2: Why is this a sustainability issue?

Obesity is a major public health concern, contributing significantly to the burden of chronic diseases and imposing substantial economic costs. Estimates indicate that obesity accounts for a staggering $1.72 trillion in direct and indirect health care expenditures in the United States, representing a hefty 9.3% of the nation's current gross domestic product (GDP) – a number that should increase to 14% in the next decade according to the OECD.

 

The staggering costs associated with obesity underscore the urgent need for effective prevention and treatment strategies. Addressing the obesity epidemic requires a multi-pronged approach that encompasses lifestyle interventions, public health policies, and accessible treatment options – like GLP-1 receptor agonists.

As we will see later in this note, these drugs are not cheap! Access to effective obesity treatment drugs is often determined by an individual's socioeconomic status. Individuals with lower incomes may face difficulties affording these medications, putting them at a disadvantage in managing their weight and improving their overall health. This could lead to a widening gap between the health outcomes of affluent and disadvantaged populations.

Moreover, the high cost of these drugs could exacerbate existing disparities in healthcare access. Individuals without adequate health insurance or with limited financial resources may be unable to access these treatments, further hindering their ability to address their weight-related health concerns.

Question #3: What is the role of insurance in getting these medicines to a wider public?

Priced between $10,000-18,000 per year, these drugs pose a financial hurdle for individuals without insurance coverage. Considering the (alarming) obesity prevalence of 40% in the U.S. population, a substantial number of people may require or desire these medications.

With 9% of the population being uninsured, public insurance plays an instrumental role through programs like Medicare and Medicaid. Medicare provides prescription drug coverage to nearly 50 million Americans but does not currently cover weight loss medications because it considers them as "lifestyle enhancers", the same as gym costs.

There has been pressure to account for weight as a health issue rather than a cosmetic one. Obesity was classified as a disease by the American Medical Association in 2013. However, efforts to pass a Treat and Reduce Obesity Act which would cover medications for obesity covered through Medicare have been unsuccessful.

Under Medicare, 20% of people are diagnosed with obesity. The New England Journal of Medicine estimates that if 10% of these diagnosed individuals opted for a weight loss drug, it would consume nearly 10% of the Medicare’s total budget. This financial strain highlights the delicate balance that public insurers face between the potential long-term benefits and the substantial cost of covering weight loss drugs. Private insurers also appear hesitant to include these medications in their coverage.

At the current price, cost benefits of the drug remain unclear. A 2022 study by the Institute for Clinical Economic Review estimated a maximum annual cost $3818 below the annual price tag for Wegovy to be considered cost effective. Going forward, a restrictive approach appears likely, mirroring recent cases such as the Alzheimer's medication Aduhelm.

Question #4: What are the prospects for equity investments in Eli Lilly and/or Novo Nordisk?

The emergence of weight loss drugs like Eli Lilly's Mounjaro and Novo Nordisk's Ozempic marks a strategic shift for these pharmaceutical giants. Eli Lilly and Novo Nordisk's revenue are heavily concentrated in diabetes and obesity care drugs.

The graphs below highlight the expected growth that semaglutide drugs like Wegovy and Ozempic are expected to bring to Novo Nordisk. Sales forecasts anticipate that 65% of Novo Nordisk revenues will come from those obesity/diabetes drugs. A similar compound, tirzepatide, is expected to have a parallel effect for Eli Lilly, going from close to nothing to more than 40% of sales in 2025. Earnings growth is expected to follow a similar path. Both stocks are priced for rapid adoption, demand currently exceeds supply for these drugs and both companies enjoy tremendous pricing power. Price to earnings ratios are very high, reflecting anticipated strong growth based on relatively optimistic expectations.

 

What could go wrong? One might recall Fen-Phen from the 1990s - another weight-loss drug that worked by suppressing appetite. The drug had significant hype but was eventually recalled for serious side effects affecting the heart. GLPs might be less at risk as they have been used in the treatment of diabetes for at least two years now, but such examples should not be ignored.

Indeed, the current list of side effects is long (constipation, diarrhea, nausea, vomiting, headache, abdominal pain, fatigue, low blood sugar, vision changes pancreatitis, kidney failure, gallbladder issues and allergic reaction). There is also risk for thyroid cancer. Moreover, once patients stop getting injections, they generally gain back most of their weight, which could be an issue for wider adoption, i.e. could become a deterrent to new users. In sum, these drugs are a massive development, but investors should be aware that some of the hype will not materialize, especially if prices stay elevated.

A recent poll found that despite much interest in weight loss drugs, only 16% of respondents would be willing to pay out of pocket. Whether insurers cover these drugs will have a significant impact on their uptake.

Drugmakers will no doubt lobby heavily for insurance coverage and high cost is the biggest contention point for insurers. An expensive drug that a large share of the population would qualify for, for their lifetime, means significantly higher costs. While insurers do access lower prices through rebates negotiated by Pharmacy Benefit Managers, given their smaller number of insured, private insurer’s power to negotiate drug prices is weaker than the government’s.

Overall, the path to insurance coverage remains uncertain. If approved, it is likely to be accompanied by high copayments or with specific requirements such that not everyone who is obese would qualify. Limited insurance coverage for such expensive drugs could be an important hurdle to their sales growth.

Question #5: These medications act as appetite suppressants, leading many analysts to the conclusion that food companies will suffer via a loss of sales. Just how many calories are we talking about?

The largest – but certainly not the only – market for obesity drugs is the U.S. Currently, about 1.7% of Americans have been prescribed an anti-obesity medication. This number is expected to grow; Morgan Stanley estimates that in a decade, about 24 million Americans, representing 7% of the total U.S. population, will be taking a weight loss drug.

We have performed back-of-envelope calculations to understand what implications this could possibly have on the food industry using pertinent facts and necessary assumptions below: 

Using this information, we calculate that even in an ambitious scenario whereby 24 million Americans are taking a weight loss drug, the drop in total fast-food revenues is around 1% annually.

Question #6: What has been the equity market reaction so far and what should investors expect going forward?

The GLP-1 space got a one-two punch in August: Novo Nordisk released a study showing that their drug helps patients lose weight and lowers the risk of cardiovascular events, while Eli Lily earnings showed explosive demand for their drug. The equity market has since priced in robust demand for these drugs, sending their producers’ share price higher. On the flip side, investors have extrapolated that less calories being consumed will start to eat (pun intended) into the sales of snack food makers and fast-food restaurants. In October, Walmart released data showing that customers that bought Ozempic were buying less food: causing a major leg down in share price on the already weak snack food sector. As much as we are happy to see unhealthy snack companies’ share price fall, it looks like the sector is oversold on an absolute and relative basis. Similarly, given our above calculations regarding only a small potential sales loss at fast food outlets, fast food retailing stocks should not be severely negatively impacted.

The Tech Titans

In last week’s note (“The Apple Case Study: Magnificent and Sustainable?”, November 2, 2023) we delved into the sustainability efforts of Apple. This week, we turn our attention to the other giants in the “Magnificent 7”. We examine their robust performance and discuss implications for investors focused on sustainability.

The evolution from “FAANG” (Facebook, Apple, Amazon, Netflix, Google) to the Magnificent 7 (encompassing Microsoft, Nvidia, and Tesla in addition to FAANG but excluding Netflix) highlights the relentless expansion and market hegemony of these tech giants. In the current year, the Mag 7 has not just led the market but have significantly outpaced the S&P 500.

Indeed, not owning this group of companies in 2023 has been detrimental to many investors: these seven stocks are outperforming the benchmark by a wide margin. Year-to-date, virtually all the gains in the S&P 500 Index can be attributed to the Mag 7, and their weight in the index has reached all-time highs. This has been a big headache for active managers.  

The Hype

The impressive growth trajectory of the Mag 7 has been fueled by exposure to artificial intelligence (AI) and cloud computing, areas experiencing explosive growth. Despite pressure from rising bond yields on tech stocks’ long duration and their steep valuations compared to the equity benchmarks, money continues to chase their share price higher. The Mag 7 has also been boosted by financial market participants’ pricing of a soft landing and benefit from passive flows that buy the benchmark. Their outsized impact on the market indices and investment portfolios presents a complex scenario: the Mag 7 serves as both a propeller of growth and a potential amplifier of systemic risk because of their sheer market weight. Furthermore, there is an extra layer of complexity as the sheer size of these companies brings greater scrutiny and greater regulatory risks.

Navigating Legal Waters

As pioneers in innovation, the Mag 7 tech stocks are increasingly encountering legal challenges. The volume and nature of litigation these companies face is reflective of their operational scale, and their aggressive pursuit of market share through anti-competitive behavior. Patent disputes are common, often stemming from the high-stakes race to secure intellectual property rights. President Biden's administration is intensifying scrutiny on monopolistic practices, resulting in a proliferation of antitrust and competition-related legal actions. This is mirrored in the uptrend of legal cases for some companies since 2021 (see chart below).

The prevalence of patent and antitrust lawsuits of the Mag 7 bear significant implications. The risks include potential financial liabilities and also risks to reputation, regulatory compliance, and business models.

Meta, Amazon, and Alphabet have seen the greatest increase in the number of litigations in the past few years. Specific examples for each company are described below:

Meta: Meta is facing lawsuits from 41 states, claiming the company's social media platforms, particularly Instagram and Facebook, are addictive and harm children's mental health. Consequences for Meta may include the implementation of stringent age verification systems, modified content algorithms to reduce addictive tendencies, and clear labeling of digital health risks. Such reforms could diminish user engagement and advertising revenue, directly affecting stock valuation.

Amazon: Amazon is accused of using a secret pricing algorithm ("Project Nessie") to inflate prices, with the FTC lawsuit suggesting the company earned over $1 billion from this practice. A ruling against the company could result in orders to dismantle or significantly alter its pricing algorithms, increased regulatory oversight, and compensation for affected customers. For Amazon, this could lead to lower profit margins, a loss of competitive advantage, and a decrease in market share.

Alphabet: Alphabet is under scrutiny for antitrust issues, with the DOJ filing a lawsuit over its advertising and search engine practices. If Alphabet is found to have violated antitrust laws with its advertising and search practices, the company could be required to separate parts of its advertising business and alter its search algorithm to ensure fairer competition – akin to what happened to Microsoft in 2000. The implications for Alphabet may involve a reconfiguration of its core business model and a decrease in ad revenue growth. For shareholders, the risks are tied to potential drops in share price and future earnings, coupled with the uncertainty of Alphabet’s strategic direction in a more regulated environment.

Investors must consider the potential for substantial regulatory shifts and financial penalties that could impact the operations and valuations of these tech giants. Furthermore, these issues bring into question the place of these companies in sustainability funds.

Sustainability: Seeing Through the Haze

The technology giants have a noteworthy presence in sustainable investment funds. The Mag 7 stocks are prominently featured in funds adhering to the Sustainable Finance Disclosure Regulation (SFDR) Articles 8 and 9 as depicted in the following table:

However, using a double materiality approach, i.e. one that considers both the operational performance and the impact the companies’ products and services have on the planet and its people, we uncover a different conclusion. The broad inclusion of these stocks in sustainability-focused funds may be somewhat dubious.

According to our double materiality analysis, Microsoft and Nvidia emerge as leaders compared to their Magnificent 7 peers. They show positive alignment with sustainability both operationally and through their products and services. Conversely, Amazon and Meta display significant challenges, warranting caution for investors seeking to prioritize sustainability. Apple, Alphabet, and Tesla present a mixed landscape, with commendable initiatives overshadowed by areas of concern (see the Apple case study note from November 02, 2023, for a detailed breakdown of Apple).

What Should a Sustainable Investor Do?

Based on the above analysis, a sustainable investor’s choices in the Mag 7 are somewhat slim, even before considering what the extremely lofty valuations of these companies (see table below). Amazon and Meta are not appropriate as long positions in a sustainable strategy. For investors that hold companies that we view as neutral regarding sustainability (Tesla, Apple and Alphabet), only Alphabet looks interesting based on its growth expectations relative to forward P/E. Telsa’s high P/E isn’t justified by its growth expectations, while Apple is not growing at all, failing to justify its premium valuation over the market. As for the only two companies of the Mag 7 that we do view as sustainable: Microsoft looks like the safer bet as it still has many avenues to continue growing. Nvidia is trading on a lot of AI hype, and we don’t believe that its growth expectations will be able to be met. For investors that can short sell, an interesting pair trade would be to buy Microsoft and short Amazon: both have been growing in cloud computing, but Microsoft has the added AI potential, while Amazon has the negative of slower consumer spending and regulation overhang.

In the first of our Strategic Asset Allocation “SAA” notes series: “Climate Change and Strategic Asset Allocation” published on August 24th, 2023, we looked at the likely effects of climate change on different asset classes. We focused on the expected rate of return that large asset owners use to establish their strategic allocation. Building on this, this note recalls the evolution of “SAA” over the last 50 years. This historical perspective reveals how asset allocation has changed in response to market dynamics and economic influences; it also provides clues to what will be necessary to deliver adequate returns in the future.

Current Positioning

The chart below highlights the evolution of the typical U.S. pension fund since 1980. The 1980s and 1990s were dominated by equities and bonds. Starting in 2000, alternatives started to occupy a much larger part of the portfolio and their share has continued to grow since. Alternatives were first introduced to diversify portfolios, but after the Great Financial Crisis, they were increasingly used to compensate for low government bond yields. The smoothed and infrequent pricing of illiquid assets was an added benefit that also contributed to their increased allocation.  

The following table highlights how allocation to assets has evolved over the past few decades:

To this day, pension funds continue to expand on these strategies, implying expectations for a continued low inflation, low interest rate environment. However, we believe that the low inflation-low interest rate environment is over for the foreseeable future.

In our previous SAA note, we emphasized the need to comprehend the factors influencing long-term returns. In addition to climate change, fiscal dominance, demographics, deglobalization and national security are all intertwined factors that will affect portfolio returns more significantly in the future.  

Fiscal Dominance

As we have shown in the past (see Macro Goes ESG, July 8th 2021), many of the challenges of the next decade will be met with fiscal policy, given that monetary policy is ineffective at addressing important issues like climate change, structural worker shortages, protectionism, rising income inequality, etc. The increasing importance of fiscal policy implies government decisions will have a greater impact on investment returns.

The accompanying chart underscores this shift in importance of fiscal policy: fiscal deficits as a percentage of GDP are getting steadily larger.

When fiscal policy dominates, winners and losers become apparent across various sectors and companies, emphasizing the need for sector-specific insights to guide allocation strategies. Voter preferences, increasingly aligned with sustainability principles, steer fiscal policies, thus elevating the significance of sustainability considerations as drivers of investment strategies. Additionally, the focus on infrastructure spending as a prominent fiscal tool spotlights sectors poised to benefit which, in turn, should influence allocation decisions.

Bottom line: A growing role for fiscal policy can be inflationary and a political economy creates winners vs. losers. In this environment, absolute return strategies that can be nimble in face of changing political winds have to the potential to outperform.

Demographics

Rapidly aging populations and declining birth rates could potentially lead to a shrinking workforce in developed countries, resulting in structural labor shortages and increased wages. Moreover, an aging population typically requires more healthcare services, often provided by the government sector via taxation. The table below highlights the evolution since the 1950s of the ratio of incoming workers compared to retiring workers in the United States, Germany, China and Japan. The period of excess labor ended at the beginning of the century in Japan and Germany but the impact was mitigated by the arrival of cost-effective Chinese labor. As we look forward, the relative wage suppression of the past may give place to greater worker wage negotiating power.

Bottom line: Structural labor shortages associated with aging populations are proving to be inflationary and it is so far very uncertain about the extent to which automation and AI can offer an offset.

Deglobalization

After decades of globalization's steady rise, there is a discernible trend towards reduced international interdependence, as shown in the chart below.

The promulgation of the Inflation Reduction Act (IRA) in 2022 is likely to reinforce this trend, given its focus on bolstering U.S. domestic production.

Deglobalization means heightened volatility for financial markets due to the potential for trade tensions and less predictability in supply chains, at least during the transition phase. In recent decades, geographical asset allocation decisions were driven primarily by a country’s potential growth rate and its ability to export to either the U.S. or China. In the future, desired exposure to a particular geography will depend more on other factors such as the healthiness of its trade relations, its ability to secure resources, its access to frontier technologies, etc. In other words, it means the focus will be on a country’s ability to replicate production capacity that was previously provided by trading partners.

Bottom line: The transition to reduced globalization is inflationary as production capacity will be replicated, displaced and/or replaced. The value of critical resources like agricultural land and other commodities will accrue, making commodities and agriculture an attractive asset class. In addition, a return to manufacturing and other basic industries within developed economies means that many companies in established industries, i.e. “value stocks” have powerful tailwinds working in their favor.

Conflicts

After World War II, the world experienced a period of relative calm, although it was punctuated by significant armed conflicts, such as the Korean War and the Vietnam War. However, According to the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) more state-based conflict-related deaths took place last year than in any year since 1994 and the world has witnessed a worrying increase in state-based conflicts in the past decade, with over 50 such conflicts each year for the past eight years.  

The map below highlights the countries where conflicts have erupted (Russia-Ukraine, Azerbaijan-Armenia, Serbia-Kosovo, Israel-Palestine) since February 2022 and where coups have taken place (Gabon, Niger, Sudan).

Conflicts have significant repercussions on material procurement and global supply chains. Disruptions in regions embroiled in conflict can lead to interruptions in the production and transportation of critical materials and resources, affecting populations, industries and businesses worldwide.

Bottom line: Beyond the terrible humanitarian toll of armed conflicts, military actions are inherently inflationary as the cost to finance war as well as the funding necessary to reconstruct puts a burden on public finances. Agriculture and natural resources, particularly those that act as a store of value, will likely be in higher demand.

Transition Phase

In our previous discussion on strategic asset allocation (SAA), we explored the impact of climate change on portfolio decisions. Beyond climate change, many of the major developments that were discussed in this note – fiscal policy importance, demographics, reshoring, armed conflicts – will affect the risk/reward backdrop for various asset classes, primarily via the long-term trend change in inflation.

The trends of the past are still shaping strategic allocation decisions today and pensions may be underestimating the effect of the changes we are witnessing. The implied assumption of many current SAAs is that we are going back to 2019 with low inflation, slow growth and low interest rates. On the contrary, at Sustainable Market Strategies we expect that climate change, fiscal dominance, demographics, and geopolitical volatility will force a transition to a more inflationary regime. In this context, we believe a shift to strategies geared to inflation protection is warranted.

 

In our last quarterly macro meets sustainability update – published June 15, 2023 – we noted that, “the AI fuelled rally in tech stocks may have some juice left, but the threat of further central bank hawkishness means that the risk/reward trade-off of betting on further gains is deteriorating”.

The quarter played out much as we expected: tech stocks continued to rally until end-July and a more aggressive U.S. bond issuance plan in the summer, along with a hawkish tone at the Fed’s September meeting finally triggered higher interest rates and, what we expect to be, a more meaningful setback in the most interest-rate sensitive sectors of the equity market.

Indeed, since our June note U.S. bond yields have moved over 100 bps higher, WTI oil price is over $15 higher and USD has surged as interest rate differentials between the U.S. and most of its trading partners have widened.

The recent backup in interest rates, so far is comparable to what was experienced last year at this time, but with the main difference being that the underpinnings of the economy are somewhat less healthy. While the job market is still robust, consumers are beginning to report that finding a job is not so easy and the enormous cash pile that was built up during the pandemic is now being spent down.  

We expect households will once again trim discretionary spending, especially since the cost of essentials – interest payments, fuel and food – continue to take a bigger portion of budgets.

Higher interest rates provide an excellent opportunity to short sell or underweight consumer discretionary stocks, especially those with questionable sustainability practices. After all, the sector’s name says it all: companies that operate in the consumer discretionary sector provide unessential products and services that will be cut back when consumer budgets tighten. From a sustainability perspective, no matter how nice the CSR report, business models that promote excessive consumption work against environmental and social good.

This thesis temporarily panned out last autumn when interest rates moved higher – see the chart below - but we expect the current underperformance period to be more pernicious for the reasons described above.

Thus, we continue to advocate for short positions in consumer discretionary stocks, with a particular penchant to “punish” greenwashers. Companies like LVMH and NIKE consistently allocate hefty budgets to marketing departments because they surely know that for the fashion industry, truly being “green” - by internalizing the true costs of production like water, chemical pollution, and in some cases, labor - is far more expensive than looking green. The current macroeconomic backdrop aligns with our negative views on these companies’ sustainability.

While higher interest rates provide an excellent opportunity to short sell or underweight greenwashing consumers, the interest rate environment risks also becoming unfavorable for companies that are leading the energy transition. Specifically, with interest rates spiking, the attractiveness of many renewable energy projects has diminished. Below, we evaluate the extent to which the rising cost of debt is likely to hinder the renewable energy transition.

Interest Rates are a Headwind to “Green” Themes…

An important difference between renewable energy and conventional energy for electricity (coal, natural gas) is that the cost of electricity generated by renewables depends largely on the cost of financing (due to large initial infrastructure outlays for long duration assets with low running costs thanks to “free” inputs like wind and sun) whereas conventional electricity depends to a much greater extent on the cost of the underlying fuel. The chart below shows the share of input costs for major energy types.

Debt comprises between over 80% of capital expenditures for wind and solar projects and, in the U.S., most of both utility-scale solar and onshore wind projects have been installed since 2009, a period with historically low interest rates. Current installed projects are reportedly well shielded from rising interest rates, since although they were financed with floating rates, most of the loans are hedged with swaps to lock in lower rates. However, the economics of new projects will clearly be affected by higher borrowing costs.

Interestingly, survey data from IRENA, that covers a wide array of renewable energy finance and industry professionals, shows that the consensus expects lower financing costs in the years ahead (onshore wind in North America and the Middle East and Africa are notable exceptions, see the chart below). The implication that if the interest rate backdrop remains hawkish, renewable energy execs will be in store for disappointment.

To be sure, higher interest rates will reduce the attractiveness of renewable energy for investors. However, we believe fears that higher interest rates will slow the energy transition are overblown.  For one thing, subsidies to the renewable energy sector will act as a powerful offset. As the chart below shows, subsidies to the renewable energy sector continue to increase, while shrinking or plateauing for non-renewable energies.

For another, regulation and social acceptability mean that the appetite for fossil-fuel generated electricity is fading fast. There are few countries in the world that still have plans to build new coal-fired power plants (China is the major exception) and plans for natural gas plants are also on the wane.

The key point is that a higher interest rate environment will no doubt reduce the expected return on renewable energy projects and slow the investment cycle. However, the higher cost of capital will not change preferences for renewable projects relative to non-renewable projects: the barriers facing conventional energy projects are much larger than simply the cost of capital.

…But A Tailwind for Insurance?

Finding sustainability plays that will outright win if rates continue to rise is no small feat. However, insurance names can sometimes flourish during rising rate environments, and those that have a head start on integrating and pricing climate risks should be of particular interest to sustainability-minded investors. In our June 29th Note (Climate Adaptation: A Way to Make Your Portfolio (And Our Infrastructure) More Resilient), we showed how some insurance companies have seen climate risks coming and built new risk models within insurance policies. For instance, Markel Group (MKL US) acquired Nephila Holdings in 2018. The latter has developed a strong expertise in natural disaster risk and has launched a number of innovative products to help manage exposure to these risks (catastrophe bonds, insurance-linked securities, weather derivatives, etc.). These are generating a new revenue stream for Markel. Another example is Willis Tower Watson (WTW US) which serves the insurance industry with risk management consulting services, including their Climate and Resilience Hub which counts more than 130 climate risk professionals.

Taking long positions to participate in the long-term success of the most prepared insurance companies is one way sustainability-focused investors can position for any further rate rise.

The term greenwashing has gained attention over the past few years, but the world of corporate “washing” spans a far more vibrant spectrum of colors.

In May 2023, as part of their preparations for Pride Month, retail giant Target introduced a range of LGBTQ-themed merchandise, ostensibly to show their support for the cause. However, their actions took a different turn when they faced substantial customer backlash. In response, Target then removed these items from shelves. But this just further amplified the controversy: by not standing their ground, the company then faced additional criticism from LGBTQ supporters.

This one example underscores the complexity of corporations engaging in marketing related to social causes. Is support genuine or merely a marketing tactic? In the case of Target, there were no meaningful incentives for LGBTQ+ employees, but merely rainbow-colored products and marketing campaigns: a potential candidate of “rainbow washing”.

Washing- whatever the colour – should not be construed merely as an unsuccessful marketing campaign. Washing is a deliberate and deceptive strategy where companies falsely tout their environmental or social responsibility to attract conscious consumers, all while seeking to bolster sales and reputation without making substantial improvements. In contrast, an unsuccessful marketing campaign typically stems from poor planning or execution, failing to resonate with the intended audience due to messaging flaws or product-marketing mismatches. An unsuccessful marketing campaign might lead to missed business objectives but typically lacks the deceptive nature of washing.

Washing comes in many colours, as the table below highlights.

The Allure of Washing

Although 2022 was marked by greater criticism of “ESG”, there is nonetheless an ongoing incentive for companies to pursue sustainability strategies. There is a consistent perception that companies that pursue lower carbon footprints merit a “greenium” and tend to have higher valuations than those that do not. Consequently, if management believes their stock price will be rewarded, there is a clear incentive for companies to pursue implementation of ESG business strategies - or at the very least, pursue an image of implementing ESG strategies.

Washing occurs when there is information asymmetry. When a seller has greater knowledge than the buyer, the seller can charge a premium for products or services. In an environment where specific, sometimes difficult to verify, product or service traits are desired, there can be a high incentive for a company to make its products more attractive to increase sales volumes, charge higher prices, and/or retain workers inspired by strong sustainability credibility.

Ultimately, if washing is successful at doing the above, then it will have a positive impact on a company’s stock price – so long as the firm does not get caught. A 2022 study of SP1500 companies showed just that: the authors  divided companies between those that greenwash without repercussion and those that don’t, it was found that the financial market reaction was positive in the medium term (i.e., six months) for the companies that greenwash.

The Deterrent to Washing

What about those that do get caught?

There are two main ways that greenwashing gets punished. The first is through a company’s social license to operate, i.e. their reputation. Quantifying the value of reputation and reputational risks is a daunting task, but one straightforward way is to consider changes in the goodwill value of a company. Goodwill refers to the value a company derives from its brand, customer base and reputation associated with its intellectual property. Third-party sources also estimate the value of brands and have shown that “greenwashing” affects this metric. For example, in the wake of Volkwswagen’s Dieselgate, Brand Finance estimated that in 2015, VW’s brand value dropped from $31 billion to $21 billion. While this is impressive, keep in mind that in the same year, VW’s non-current assets were over 230 million euros:  the overall balance sheet effect of their brand loss shouldn’t be overstated.

The second way that greenwashing gets punished is through litigation. One example is the Keurig class action suit that settled in 2022. Keurig Doctor Pepper (KDP US) deceptively advertised its K-Cups coffee pods’ recyclability by misleadingly labeling and marketing them as “recyclable” when the pods were not actually accepted for recycling in most municipalities. The complaint was filed in December, 2018 and was settled in February, 2022; the company agreed to pay USD 10 million. Coffee product sales represent about one-third of the company’s revenues (total company sales were about USD 14 billion in 2022).

The chart below shows the stock performance of KDP at the time of the announced lawsuit, during the proceedings and after the case; the company’s results are hardly distinguishable from its peers in the rest of the beverage industry!  

A second example of washing litigation is the case of Credit Acceptance Corporation (CACC), which, over the past three years, faced no less than four significant litigations, each related to its business practices within the automotive lending sector. These controversies have raised questions about compliance, consumer relations, and predatory lending. Note that contrary to Keurig, where the lawsuit did not question the legitimacy of the company’s product (coffee), the CACC cases were all aimed directly at the service provided. The effect of legal proceedings on CACC's stock price have been pronounced, with declines exceeding 10% in three out of four cases, as shown in the chart below.

The Net Present Value Of Greenwashing: Currently Positive, But….

The above examples show that the penalty for washing, as measured by stock market return, can range from paltry (Keurig) to material (CACC).  We expect, however, that the deterrence to washing is about to become more substantial.

Investors can think about washing in financial terminology. The net present value (NPV) of washing, for most companies, has been net positive: the projected earnings generated by washing activities - misleading marketing campaigns, making donations to improve a company’s corporate image, other investments made to appear more sustainable - exceed the anticipated costs.

But the costs of getting caught are beginning to rise, making the NPV less favorable. For one thing, the number of greenwashing cases that end up in litigation is surging. Climate litigation in general is skyrocketing higher, and greenwashing cases are a rising portion within that trend. The chart below shows the number of greenwashing cases that are in litigation.

Moreover, greenwashing cases are increasingly being reported on by media, implying that the public is far more aware of the practice.

Importantly, although the  Securities and Exchange Commission (SEC) has yet to finalize proposed new rules for company disclosures regarding environmental, social, and governance (ESG) policies, last November, the SEC gained broader authority under the Marketing Rule to examine all of firms’ compliance processes for advertising and marketing material, including ESG claims. In addition, the SEC has also created a 22-member Climate and ESG Task Force in its Division of Enforcement to better monitor firms’ and issuers’ ESG practices. On their website, they cite six examples of enforcement actions that occurred in 2022 alone. These range from an Adviser charged for failing to follow its policies and procedures involving ESG investments to a health insurance distributor and former CEO charged with making false statements to investors as well as a sham environmentally-friendly bottling company.

In Europe, rooting out washing is further advanced. In the financial sector, the Sustainable Finance Disclosure Regulation (SFDR) has been in effect since 2021 and gives transparency to investors on how providers and products affect the environment and society. In addition, the European Commission published a proposal for a Green Claims Directive in the spring 2023, with the goal to ensuring that environmental labels and claims are credible and trustworthy.

The past decade has witnessed remarkable progress in access to financial services around the world. Technological developments led to a growing number of FinTech platforms that enabled a greater number of poorly-served people to access financial services. New service providers increased competition for several different platforms – bank transfers, electronic payments, cell phones, etc. – in countries where such choices are available. These developments were useful to 1) empower consumers; 2) extend the reach of financial services to a greater share of the population; and 3) lower transaction costs. Today, the most underserved individuals with regard to access to financial services are found in Asia and Sub-Saharan Africa.

Despite this progress, it is still challenging to qualify the extent to which companies in the financial sector can have an “impact”. At Sustainable Market Strategies, we designed a matrix that shows the many ways a financial company can have impact according to the services they provide in developed, developing and frontier markets.

From our perspective, financial companies who “push the envelope” and look to increase their reach by growing their exposure to the underserved are considered impactful. For example, the penetration rate of mobile money services in regions such as Sub-Saharan Africa is a testament to the impact of such services on those populations. Airtel Africa is an example of a Telecom company which provides a fair amount of financial services to its client base.

In developed markets, financial companies can typically be considered impactful if they provide services to lower-income “unbanked” and/or “underbanked” populations. For their part, insurance companies who establish methods to limit price increases of their premiums and ensure coverage in higher-risk areas (i.e. areas with higher crime rates, lower incomes, and greater climate risks) would be considered impactful. This is especially relevant in the U.S. where a growing number of people are going uninsured.

 

In emerging and frontier markets, banks with specific outreach programs such as microfinance business streams and/or payment/transfer/mobile phone companies that facilitate the availability of services via digital platforms are considered impactful because of their contribution in elevating people out of poverty. Additionally, financial companies that facilitate and/or lower the costs of P2P transfers between DMs and EMs/FMs are also considered impactful as the provision of low-cost international transfer services could enable greater financial flows from DMs towards EMs and FMs.

 

In today’s note, we look at three investment ideas whereby investors looking to have an impact can invest in the financial sector: Community Banks, EM/FM banks and transfer payment providers. This note builds on our previous analysis of the financial sector (see our note “Three (Sexy) Banking Plays to Change the World” September 8, 2022).

Idea #1: DMs/US Community Banks

Community banks typically cater to regional communities across the United States. With their loan portfolio and deposit base “close to home”, these institutions are often very familiar with the people they serve and their regional markets. That said, recent wobbles in the U.S. banking system and the more stringent funding requirements have hit this sector hard. Furthermore, many communities and regional banks have a relatively high exposure to commercial real estate – which remains itself under stress as the asset class continues to re-price. Thus, it is not surprising that U.S. community banks have underperformed the overall sector in the U.S. – and globally – over the past year. 

It is difficult to see a good entry point into U.S. community banks at this juncture. After all, persistently high interest rates should continue to create problems in their loan portfolios as well as challenge their asset and liability matching over the next few months.

Idea #2: EMs/FMs Banks

To have in impact, one could also consider investing in EMs/FMs banks that are leading the pack with regard to financial inclusion. While country-level data on financial inclusion is made available by organisations such as the WorldBank or the IMF, bank-level data on financial inclusion remains scarce. That said, sustainably-minded investors looking to invest in financial institutions with a view to promote financial inclusiveness could look into some data published by the World Bank, as highlighted in the table below.

With this in mind, EMs/FMs banks really ought to disclose more data on financial inclusion as a means to grow their investors’ base. Looking at recent pricing trends in global banking stocks, one can see that banks have underperformed the global equity market these past few months – especially EM banks. While interest rates have not “normalized” as much in EMs as they have may have done in DMs, one can think that (in absence of issues around financial stability and excluding Chinese banks) higher-for-longer interest rates could help EM banks boost their net interest margins in the coming months. This should contribute positively to their profit margins going forward.

Finally, we look at financial inclusiveness mentions in Financials’ sector filings included in the MSCI FM and EM indices. Interestingly, mentions of financial inclusion are about absent in U.S. banks filings. Aside from financial institutions such as VISA, it is hard to believe that U.S. financial institutions – such as Goldman Sachs or BlackRock – are really putting financial inclusion high up on their agenda.

Conversely, mentions of financial inclusiveness are much more prevalent in EM and FM financial insitutions’ filings.

This seems especially true for institutions such as the Commercial International Bank (Egypt) and Creditcorp (Peru), two frontier markets’ banks. Interestingly, both have outperformed the MSCI Frontier index this past year and for investors ready to look for financial inclusiveness plays on the margins – these institutions could prove a smart way to address financial inclusiveness through publicly-listed banks in the frontier space.

Idea #3: Transfer payment companies

Recent developments in FinTech and the strong growth of the global market for remittances gave a boost to transfer payments companies – especially those looking to shave off costs on international money transfers. A recent compilation of newcomers in the transfer payment market suggests that these firms’ markup on international transfers varies from 0 to 1.5%. This compares to about 1-6% using the mid-market FX rate for a traditional transfer company such as Western Union. As a result, the market for global remittances has gotten much more competitive – and this comes to the benefit of users of such platforms.

From an impact perspective, one could favor transfer payment companies that offer the possibility to do P2P transfers from DMs to EMs at a lower cost. While companies like Western Union provide the biggest outreach in the remotest part of the planet – they are also the most expensive service in the sector. Conversely, upcomers such as Wise payments, which enables transfers to a wide range of geographies and currencies – offer discount transfer and FX rates and are quickly gaining market share as their service is offered in an increasing number of currencies. For its part, Remitly offers the possibility to send and receive money transfers – but just for users in the U.S. at this point – which makes it less interesting from an impact perspective. Despite the sector’s tailwinds coming from the growing global remittance markets and low-cost international financial transfers, these companies have underperformed the NASDAQ over the past year – aside for Remitly and Wise. Interestingly, some money transfer companies display hefty profit margins, hovering around 20%, which could make an interesting investment opportunity.

Looking at valuation, newcomers appear expensive against more established players. No doubt that market participants are pricing an outcome whereby lower-cost alternatives such as Wise, Remitly and others rapidly displace “old school” companies such as Western Union.